A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

Inclusion Criteria: * Participants must have a body mass index between 18 and 32 kg/m2. * Participants must be healthy, as determined by physical examination, vital signs, ECGs, and clinical laboratory assessments. * Participants must be willing and able to adhere to the prohibitions and restrictions specified in the protocol. Exclusion Criteria: * Participants must not have any significant acute or chronic medical illness. * Participants must not have any current or recent (within 3 months of study intervention administration) gastrointestinal disease including, but not limited to, bowel obstruction or perforation, gastrointestinal ulcers, esophageal varices, Crohn's disease, diverticulitis, irritable bowel syndrome, ileus, a gastrointestinal tract that is not anatomically intact, dyspepsia, constipation, diarrhea, or vomiting. * Participants must not be intolerant or allergic to lidocaine or cetacaine or any type of topical anesthetic. Other protocol-defined inclusion/exclusion criteria apply